← Back to Search

Anti-tumor antibiotic

Chemotherapy for Breast Cancer

N/A

Waitlist Available

Led By Susan Love, MD, MBA

Research Sponsored by Dr. Susan Love Research Foundation

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Must be able to undergo necessary surgery

No pathological invasive or microinvasive disease in the affected breast

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is testing a chemotherapy drug to see if it can reduce the size of tumors in women with a certain type of breast cancer.

Who is the study for?

This trial is for women with a type of breast cancer called ductal carcinoma in situ who haven't had previous surgery or radiotherapy on the affected breast, no prior chemo within the last year, and are not pregnant. They must be able to have surgery and should not be currently participating in other drug trials.Check my eligibility

What is being tested?

The trial is testing doxorubicin hydrochloride liposome, a chemotherapy drug given before surgery to see if it can shrink tumors effectively. The goal is to reduce tumor size so less normal tissue needs removal during surgery.See study design

What are the potential side effects?

Doxorubicin hydrochloride liposome may cause side effects such as fatigue, nausea, hair loss, mouth sores, heart problems and increased risk of infection due to low blood cell counts.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am fit for surgery.

Select...

My breast cancer has not invaded deeper tissues.

Select...

I have been diagnosed with a type of breast cancer called ductal carcinoma in situ.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Ability to identify and cannulate the duct

Efficacy

Integration of the Humboldt Community Breast Health Project into the planning and execution of this study

+1 more

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Dr. Susan Love Research FoundationLead Sponsor

2 Previous Clinical Trials

55,449 Total Patients Enrolled

1 Trials studying Breast Cancer

55,008 Patients Enrolled for Breast Cancer

Susan Love, MD, MBAPrincipal InvestigatorDr. Susan Love Research Foundation

Media Library

Doxorubicin Hydrochloride Liposome (Anti-tumor antibiotic) Clinical Trial Eligibility Overview. Trial Name: NCT00671476 — N/A

Breast Cancer Clinical Trial 2023: Doxorubicin Hydrochloride Liposome Highlights & Side Effects. Trial Name: NCT00671476 — N/A

Doxorubicin Hydrochloride Liposome (Anti-tumor antibiotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00671476 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are new participants being inducted into this research endeavor?

"According to clinicaltrials.gov, this medical research study is no longer enrolling participants as of January 9th 2014; however, there are 1486 other trials actively recruiting at present. This particular trial was initially posted on February 1st 2008."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Doxorubicin Hydrochloride Liposome in Treating Women With Ductal Carcinoma in Situ Undergoing Surgery

2008. "Doxorubicin Hydrochloride Liposome in Treating Women With Ductal Carcinoma in Situ Undergoing Surgery". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00671476.

All > Breast Cancer Anaheim > Dcis